Conclusion Of A Non-Exclusive Discount Agreement In Accordance With Section 130A Paragraph 8 Sgb V For The Active Ingredient Doravirine, Lamivudine, Tenofovir Disoproxil Fumarate, Atc J05Ar24 For The Period December 1St, 2023 - November 30Th, 2025

  Address - Germany

  Contact details - 565656565

  Tender notice no. - 76454545

  MT Ref Id - 73421408

  Document Type - Tender Notices

Description - Section 130a paragraph 8 SGB V enables health insurance companies and pharmaceutical companies to conclude framework discount agreements for the medicines to be supplied at the expense of the statutory health insurance companies. With regard to the r elevant legal regulations for the awarding of public contracts, a regular process of active ingredient-related, formal procurement procedures takes place in accordance with the regulations of Part 4 of the GWB by DAK-Gesundheit. For medicinal products to be specified by the bidder in Annex 2 to the contract in relation to the above. Active ingredient, doravirine, lamivudine, tenofovir disoproxil fumarate, ATC J05AR24, DAK-Gesundheit intends to co

Mt Ref Id - 73421408

Deadline - Oct 05, 2025